下肢旁路移植至踝旁及足部靶目标的中期结局与失败预测因素
基于血管质量倡议数据库2003至2021年数据,分析2331例下肢旁路移植至踝旁或足部靶目标的结局。靶向远端旁路占比从2003年13.37%降至2021年3.51%(P<0.001)。2年一期通畅率50.56%±3.6%,主要不良肢体事件63.49%±3.27%,无截肢生存率71.71%±0.98%。非大隐静脉移植物与通畅率丧失及主要不良肢体事件增加相关,高中心手术量(>5例/年)与2年一期通畅率改善及主要不良肢体事件降低相关。
要点
- 靶向远端下肢旁路移植占比从2003年13.37%降至2021年3.51%(P<0.001)。
- 2年一期通畅率50.56%±3.6%,主要不良肢体事件63.49%±3.27%,无截肢生存率71.71%±0.98%。
- 非大隐静脉移植物与一期通畅率丧失及主要不良肢体事件增加相关(P<0.001)。
核心结论
- 尽管使用减少,踝部远端靶目标的开放手术旁路移植仍是治疗膝下危及肢体缺血的可行选择,2年通畅率和无截肢生存率可接受。
- 远端靶目标旁路移植应在高容量中心进行,以优化移植物通畅率和保肢并减少再干预。
研究设计与样本
- 查询血管质量倡议腹股沟下数据库2003至2021年数据,识别下肢旁路移植至踝旁或足部/跖部靶目标的病例。
- 共纳入2331例下肢旁路移植手术,包括1265例踝部/足背动脉的前胫动脉旁路、783例踝部后胫动脉旁路、283例跗/跖动脉旁路。
- 主要结局为2年移植物通畅率、主要不良肢体事件(血管再干预、踝以上截肢)和无截肢生存率,采用标准统计方法分析。
主要发现
- 靶向远端下肢旁路移植占所有下肢旁路移植的比例从2003年13.37%显著降至2021年3.51%(P<0.001)。
- 大多数病例表现为组织缺损(81.25%),术后主要不良心脏事件发生率为8.9%,手术部位感染发生率为3.6%。
- 1年主要截肢发生率为16.8%,术后1年死亡率为10%。
- 未调整Kaplan-Meier生存分析显示2年一期通畅率为50.56%±3.6%,主要不良肢体事件为63.49%±3.27%,无截肢生存率为71.71%±0.98%。
- 调整分析(调整合并症、指征、移植物类型、手术紧迫性、既往血管干预、移植物流入血管(股/腘)、同期流入道手术、外科医生和中心手术量)显示,非大隐静脉移植物(P<0.001)与一期通畅率丧失和主要不良肢体事件增加相关;高中心手术量(>5例/年)与2年一期通畅率改善(P=0.015)和主要不良肢体事件降低(P=0.021)相关。
临床怎么用
- 作者认为,尽管使用减少,踝部远端靶目标的开放手术旁路移植仍是治疗膝下危及肢体缺血的可行选择,2年通畅率和无截肢生存率可接受。
- 作者建议,远端靶目标旁路移植应在高容量中心进行,以优化移植物通畅率和保肢并减少再干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The frequency of distal lower extremity bypass (LEB) for infrapopliteal critical limb threatening ischemia (IP-CLTI) has significantly decreased. Our goal was to analyze the contemporary outcomes and factors associated with failure of LEB to para-malleolar and pedal targets. METHODS: We queried the Vascular Quality Initiative infrainguinal database from 2003 to 2021 to identify LEB to para-malleolar or pedal/plantar targets. Primary outcomes were graft patency, major adverse limb events [vascular reintervention, above ankle amputation] (MALE), and amputation-free survival at 2 years. Standard statistical methods were utilized. RESULTS: We identified 2331 LEB procedures (1,265 anterior tibial at ankle/dorsalis pedis, 783 posterior tibial at ankle, 283 tarsal/plantar). The prevalence of LEB bypasses to distal targets has significantly decreased from 13.37% of all LEB procedures in 2003-3.51% in 2021 (P < 0.001). The majority of cases presented with tissue loss (81.25. Common postoperative complications included major adverse cardiac events (8.9%) and surgical site infections (3.6%). Major amputations occurred in 16.8% of patients at 1 year. Postoperative mortality at 1 year was 10%. On unadjusted Kaplan-Meier survival analysis at 2 years, primary patency was 50.56% ± 3.6%, MALE was 63.49% ± 3.27%, and amputation-free survival was 71.71% ± 0.98%. In adjusted analyses [adjusted for comorbidities, indication, conduit type, urgency, prior vascular interventions, graft inflow vessel (femoral/popliteal), concomitant inflow procedures, surgeon and center volume] conduits other than great saphenous vein (P < 0.001) were associated with loss of primary patency and increased MALE. High center volume (>5 procedures/year) was associated with improved primary patency (P = 0.015), and lower MALE (P = 0.021) at 2 years. CONCLUSIONS: Despite decreased utilization, open surgical bypass to distal targets at the ankle remains a viable option for treatment of IP-CLTI with acceptable patency and amputation-free survival rates at 2 years. Bypasses to distal targets should be performed at high volume centers to optimize graft patency and limb salvage and minimize reinterventions.
引用
- Abdul-Malak OM, Semaan DB, Madigan MC, et al. Midterm Outcomes and Predictors of Failure of Lower Extremity Bypass to Para-Malleolar and Pedal Targets. Ann Vasc Surg. 2024. PMID: 38815913. doi:10.1016/j.avsg.2024.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。